Prevalence of human papillomavirus genotypes in cervical cancer

International Journal of Gynecological Cancer

Volumn 22, Issue 6, 2012, Pages 1063-1068

  Chinchai, Teeraporn ^a   Chansaenroj, Jira ^b   Swangvaree, Sukumarn ^c   Junyangdikul, Pairoj ^d   Poovorawan, Yong ^b  

^a SRINAKHARINWIROT UNIVERSITY   (Thailand)

^b CHULALONGKORN UNIVERSITY   (Thailand)

^c NATIONAL CANCER INSTITUTE   (United States)

^d Samitivej Srinakharin Hospital   (Thailand)

Author keywords

Cervical cancer; HPV genotype; INNO LiPA; Prevalence; Thailand

Indexed keywords

VIRUS DNA;

ADULT; AGED; ARTICLE; CANCER PREVENTION; CANCER STAGING; CYTOLOGY; DNA MICROARRAY; FEMALE; GENOTYPE; HUMAN; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN PAPILLOMAVIRUS TYPE 18; HUMAN PAPILLOMAVIRUS TYPE 33; HUMAN PAPILLOMAVIRUS TYPE 52; HUMAN PAPILLOMAVIRUS TYPE 58; MAJOR CLINICAL STUDY; NONHUMAN; PAPANICOLAOU TEST; PREVALENCE; PRIORITY JOURNAL; THAILAND; UTERINE CERVIX CANCER; VERRUCA VULGARIS; WART VIRUS;

ADULT; AGED; AGED, 80 AND OVER; ALPHAPAPILLOMAVIRUS; FEMALE; GENOTYPING TECHNIQUES; HUMANS; MIDDLE AGED; PAPILLOMAVIRUS INFECTIONS; THAILAND; UTERINE CERVICAL NEOPLASMS;

EID: 84863628026     PISSN: 1048891X     EISSN: 15251438     Source Type: Journal    
DOI: 10.1097/IGC.0b013e318259d904     Document Type: Article

References (25)

1. Parkin DM, Bray F, Ferlay J, et al. Global cancer statistics. CA Cancer J Clin. 2002;55:74-108.
2. WHO. 2010. WHO/ICO Information Centre on HPV and Cervical Cancer (HPV Information Centre). Human Papillomavirus and Related Cancers in Thailand. Summary Report 2010. Available at http://apps.who.int/hpvcentre/statistics/ dynamic/ico/country-pdf/THA.pdf. Accessed May 25, 2012.
3. Smith JS, Lindsay L, Hoots B, et al. Human papillomavirus type distribution in invasive cervical cancer and high-grade cervical lesions: a meta-analysis update. Int J Cancer. 2007;121:621-632.
4. De Villiers EM, Fauquet C, Broker TR, et al. Classification of papillomaviruses. Virology. 2004;324:17-27.
5. Lin K, Roosinovich E, Ma B, et al. Therapeutic HPV DNA vaccines. Immunol Res. 2010;47:86-112.
6. Lai CH, Huang HJ, Hsueh S, et al. Human papillomavirus genotype in cervical cancer: a population-based study. Int J Cancer. 2007;120:1999-2006.
7. Koutsky LA, Ault KA, Wheeler CM, et al. A controlled trial of a human papillomavirus type 16 vaccine. N Engl J Med. 2002;347:1645-1651.
8. Villa LL, Costa RLR, Petta CA, et al. Prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in young women: a randomised double-blind placebo-controlled multicentre phase II efficacy trial. Lancet Oncol. 2005;6:271-278.
9. Harper DM, Franco EL, Wheeler C, et al. Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trial. Lancet. 2004;364:1757-1765.
10. Harper DM, Franco EL, Wheeler CM, et al. Sustained efficacy up to 4.5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial. Lancet. 2006;367:1247-1255.
11. FUTURE II Study Group. Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions. N Engl J Med. 2007;356:1915-1927. Health Bureau, Macao SAR Government.
12. Paavonen J, Jenkins D, Bosch FX, et al. Efficacy of a prophylactic adjuvanted bivalent L1 virus-like-particle vaccine against infection with human papillomavirus types 16 and 18 in young women: an interim analysis of a phase III double-blind, randomised controlled trial. Lancet. 2007;369:2161-2170.
13. Paavonen J, Naud P, Salmerón J, et al. Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young women. Lancet. 2009;374:301-314.
14. Muñoz N, Manalastas R, Pitisuttithum P, et al. Safety, immunogenicity, and efficacy of quadrivalent human papillomavirus (types 6, 11 16, 18) recombinant vaccine in women aged 24-45 years: a randomised, double-blind trial. Lancet. 2009;373:1949-1957.
15. Clifford GM, Smith JS, Plummer M, et al. Human papillomavirus types in invasive cervical cancer worldwide: a meta-analysis. Br J Cancer. 2003;88:63-73.
16. Clifford GM, Smith JS, Aguado T, et al. Comparison of HPV type distribution in high-grade cervical lesions and cervical cancer: a meta-analysis. Br J Cancer. 2003;89:101-105.
17. Smith JS, Lindsay L, Hoots B, et al. Human papillomavirus type distribution in invasive cervical cancer and high-grade cervical lesions: a meta-analysis update. Int J Cancer. 2007;121:621-632.
18. Galloway DA. Papillomavirus vaccines in clinical trials. Lancet Infect Dis. 2003;3:469-475.
19. Chinchai T, Chansaenroj J, Junyangdikul P, et al. Comparison between direct sequencing and INNO-LiPA methods for HPV detection and genotyping in Thai women. Asian Pac J Cancer Prev. 2011;12:1-6.
20. TNM Classification of malignant tumours. In: Sobin L, Wittekind Ch, eds. UICC International Union Against Cancer. 6th ed. Geneva, Switzerland: Wiley-Liss. 2002:155-157.
21. Broccolo F, Drago F, Careddu AM, et al. Additional evidence that pityriasis rosea is associated with reactivation of human herpesvirus-6 and -7. J Invest Dermatol. 2005;124:1234-1240.
22. Bhattarakosol P, Lertworapreecha M, Kitkumthorn N, et al. Survey of human papillomavirus infection in cervical intraepithelial neoplasia in Thai women. J Med Assoc Thai. 2002;85:S360YS365.
23. Sukvirach S, Smith JS, Tunsakul S, et al. Population-based human papillomavirus prevalence in Lampang and Songkla, Thailand. J Infect Dis. 2003;187:1246-1256.
24. Clifford GM, Gallus S, Herrero R, et al. Worldwide distribution of human papillomavirus types in cytologically normal women in the International Agency for Research on Cancer HPV prevalence surveys: a pooled analysis. Lancet. 2005;366:991-998.
25. Chandeying V, Garland SM, Tabrizi SN. Prevalence and typing of human papillomavirus (HPV) among female sex workers and outpatient women in southern Thailand. Sex Health. 2006;3:11-14.